Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 66

1.

Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells.

Ebine K, Kumar K, Pham TN, Shields MA, Collier KA, Shang M, DeCant BT, Urrutia R, Hwang RF, Grimaldo S, Principe DR, Grippo PJ, Bentrem DJ, Munshi HG.

Sci Rep. 2018 Sep 5;8(1):13225. doi: 10.1038/s41598-018-31658-1.

2.

Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, Munshi HG, Benson AB 3rd, O'Dwyer PJ.

JAMA Oncol. 2018 Aug 30. doi: 10.1001/jamaoncol.2018.3277. [Epub ahead of print]

PMID:
30178032
3.

KRASG12D and TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs.

Principe DR, Overgaard NH, Park AJ, Diaz AM, Torres C, McKinney R, Dorman MJ, Castellanos K, Schwind R, Dawson DW, Rana A, Maker A, Munshi HG, Rund LA, Grippo PJ, Schook LB.

Sci Rep. 2018 Aug 22;8(1):12548. doi: 10.1038/s41598-018-30916-6.

4.

Slfn2 Regulates Type I Interferon Responses by Modulating the NFĸB Pathway.

Fischietti M, Arslan AD, Sassano A, Saleiro D, Majchrzak-Kita B, Ebine K, Munshi HG, Fish EN, Platanias LC.

Mol Cell Biol. 2018 Jun 4. pii: MCB.00053-18. doi: 10.1128/MCB.00053-18. [Epub ahead of print]

PMID:
29866656
5.

TGFβ engages MEK/ERK to differentially regulate benign and malignant pancreas cell function.

Principe DR, Diaz AM, Torres C, Mangan RJ, DeCant B, McKinney R, Tsao MS, Lowy A, Munshi HG, Jung B, Grippo PJ.

Oncogene. 2017 Jul 27;36(30):4336-4348. doi: 10.1038/onc.2016.500. Epub 2017 Apr 3.

6.

BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo.

Kumar K, DeCant BT, Grippo PJ, Hwang RF, Bentrem DJ, Ebine K, Munshi HG.

JCI Insight. 2017 Feb 9;2(3):e88032. doi: 10.1172/jci.insight.88032.

7.

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects.

Abedin SM, Boddy CS, Munshi HG.

Onco Targets Ther. 2016 Sep 28;9:5943-5953. eCollection 2016. Review.

8.

Slug inhibits pancreatic cancer initiation by blocking Kras-induced acinar-ductal metaplasia.

Ebine K, Chow CR, DeCant BT, Hattaway HZ, Grippo PJ, Kumar K, Munshi HG.

Sci Rep. 2016 Jul 1;6:29133. doi: 10.1038/srep29133.

9.

Interaction of tRNA with MEK2 in pancreatic cancer cells.

Wang X, Chow CR, Ebine K, Lee J, Rosner MR, Pan T, Munshi HG.

Sci Rep. 2016 Jun 15;6:28260. doi: 10.1038/srep28260.

10.

Targeting BET bromodomain proteins in solid tumors.

Sahai V, Redig AJ, Collier KA, Eckerdt FD, Munshi HG.

Oncotarget. 2016 Aug 16;7(33):53997-54009. doi: 10.18632/oncotarget.9804. Review.

11.

Loss of TGFβ signaling promotes colon cancer progression and tumor-associated inflammation.

Principe DR, DeCant B, Staudacher J, Vitello D, Mangan RJ, Wayne EA, Mascariñas E, Diaz AM, Bauer J, McKinney RD, Khazaie K, Pasche B, Dawson DW, Munshi HG, Grippo PJ, Jung B.

Oncotarget. 2017 Jan 17;8(3):3826-3839. doi: 10.18632/oncotarget.9830.

12.

PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction.

Principe DR, DeCant B, Diaz AM, Mangan RJ, Hwang R, Lowy A, Shetuni BB, Sreekumar BK, Chung C, Bentrem DJ, Munshi HG, Jung B, Grippo PJ, Bishehsari F.

Oncotarget. 2016 May 10;7(19):28218-34. doi: 10.18632/oncotarget.8587.

13.

TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis.

Principe DR, DeCant B, Mascariñas E, Wayne EA, Diaz AM, Akagi N, Hwang R, Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi HG, Jung B, Grippo PJ.

Cancer Res. 2016 May 1;76(9):2525-39. doi: 10.1158/0008-5472.CAN-15-1293. Epub 2016 Mar 15.

14.

Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer.

Kumar K, Chow CR, Ebine K, Arslan AD, Kwok B, Bentrem DJ, Eckerdt FD, Platanias LC, Munshi HG.

Mol Cancer Res. 2016 Feb;14(2):216-27. doi: 10.1158/1541-7786.MCR-15-0285. Epub 2015 Nov 25.

15.

Cancer Cell Invasion in Three-dimensional Collagen Is Regulated Differentially by Gα13 Protein and Discoidin Domain Receptor 1-Par3 Protein Signaling.

Chow CR, Ebine K, Knab LM, Bentrem DJ, Kumar K, Munshi HG.

J Biol Chem. 2016 Jan 22;291(4):1605-18. doi: 10.1074/jbc.M115.669606. Epub 2015 Nov 20.

16.

Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells.

Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG, Verma AK, Platanias LC.

Mol Cell Biol. 2015 Aug;35(15):2684-98. doi: 10.1128/MCB.00019-15. Epub 2015 May 26.

17.

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.

Kumar K, Raza SS, Knab LM, Chow CR, Kwok B, Bentrem DJ, Popovic R, Ebine K, Licht JD, Munshi HG.

Sci Rep. 2015 Mar 25;5:9489. doi: 10.1038/srep09489.

18.

Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation.

Gounaris E, Heiferman MJ, Heiferman JR, Shrivastav M, Vitello D, Blatner NR, Knab LM, Phillips JD, Cheon EC, Grippo PJ, Khazaie K, Munshi HG, Bentrem DJ.

PLoS One. 2015 Mar 6;10(3):e0121402. doi: 10.1371/journal.pone.0121402. eCollection 2015.

19.

Comparative effectiveness in esophagogastric cancer.

Knab LM, Belotte J, Munshi HG, Bentrem DJ.

Cancer Treat Res. 2015;164:121-42. doi: 10.1007/978-3-319-12553-4_8.

PMID:
25677022
20.

Ablation of 5-lipoxygenase mitigates pancreatic lesion development.

Knab LM, Schultz M, Principe DR, Mascarinas WE, Gounaris E, Munshi HG, Grippo PJ, Bentrem DJ.

J Surg Res. 2015 Apr;194(2):481-7. doi: 10.1016/j.jss.2014.10.021. Epub 2014 Oct 22.

Supplemental Content

Loading ...
Support Center